GDM: Abnormal Glucose Tolerance During Pregnancy (2008)

Citation:
 
Study Design:
Class:
- Click here for explanation of classification scheme.
Quality Rating:
Research Purpose:

To investigate the maternal demographic and metabolic factors contributing to the growth of fetal and fat body mass in women whose degree of glucose intolerance is less than that defining gestational diabetes in comparison with women with normal glucose metabolism.

 

Inclusion Criteria:
  • Caucasian
  • Singleton pregnancies without congenital malformations
  • Gestational age confirmed by first trimester ultrasound
  • Absence of gestational diabetes based on the criteria of Carpenter and Coustan
  • Two or more previous deliveries
  • Pregestational BMI between 19 and 25 kg/m2 
  • Absence of tobacco use
  • Absence of previous gestational diabetes
  • The study protocol was approved by the hospital institutional review board and written consent was obtained from each subject before participation in the study protocol.
  • On the basis of GCT results, the 189 selected women were separated into 2 groups. Group 1 comprised 66 women with an abnormal GCT value (plasma glucose level > 135 mg/dL after 1 h) followed by negative 100-g GTT. Group 2 comprised 123 women with a normal GCT value.

     

Exclusion Criteria:

Among the 39 women excluded, 25 decided to discontinue the study protocol, 5 did not deliver at the clinic, and 9 had spontaneous preterm delivery.

 

Description of Study Protocol:

Recruitment 

In the period between January 1999 and December 2001, a population of pregnant women was screened for gestational diabetes between the 24th and 28th week of pregnancy with a 50-g, 1-h oral glucose challenge test (GCT) at the Perinatal Medicine Unit of the University of Florence.

Design Prospective Cohort

Blinding used The sonographers did not know to which group the women belonged.

Intervention:  not applicable  

Statistical Analysis 

  • Continuous variables were compared with either Student’s t or Mann-Whitney U test.
  • Categorical variables were tested with either X2 or Fisher’s exact test.
  • Multivariate logistic regression analysis established best-fit equations for fetal sonographic measurements of fat and lean body mass. A P <0.05 was considered statistically significant.
  • Statistical analysis was performed by Stata statistical software release 5.0 (Stata, College Station, TX)
Data Collection Summary:

Timing of Measurements

  • Measurements were obtained before meals, 1 and 2 h after meals, and every 2 h in the afternoon and during the night.
  • After each visit, an ultrasound scan was performed, and the 24-h capillary glucose profile obtained by the subjects at home were performed.

Dependent Variables

  • GCT and glucose tolerance test (GTT) - plasma glucose determinations were performed in the clinical laboratory of the hospital with the glucose oxidase method, using an automated system (Aeroset; Abbott laboratories, Abbott Park, Il) with inter-and intra-assay coefficients of variation (CVs) of 0.8%.
  • Following the GCT, subjects were seen 3-week intervals in the period between 24 and 38 weeks.
  • Women were asked to have three main meals at 8:00 A.M, noon, and 8:00 P.M, and to perform a 24-h glucose profile on the day preceding the ultrasound scan using a memory based reflectance meter (one Touch Profile; Lifescan, Milpitas, CA) with tested precision and accuracy (CV 3.0-4.0% and coefficient correlation 0.981, respectively) without modifying their lifestyle or following any dietary restriction. Measurements were obtained before meals, 1 and 2 h after meals, and every 2 h in the afternoon and during the night.
  • After each visit, an ultrasound scan was performed, and the 24-h capillary glucose profile obtained by the subjects at home were performed. Ultrasound scans were performed using a commercially available, unmodified Teknos Esaote ultrasound machine (Easote, Genoa, Italy) with a 3.5 MHz transducer.
  • Established techniques Bernstein and colleagues to measure the fat and lean body mass areas on axial ultrasound images of the mid-upper arm, the mid-upper leg, and the anterior abdominal wall thickness.
  • At least two measurements (except for 4 observations for anterior abdominal wall thickness).  were made for each parameter at each observation. The mean value of each set of observations was used in the analysis. 848 Ultrasonographic examination and 848 24-h glucose profiles examination (mean number per subject 4.5, range 3-6 for both). Two operators performed the ultra sound examinations.
  • The intra- and interobserver reproducibility of the measurements were tested in 20 different images. Precision was assessed as the coefficients of variation (CV) of previous measurements.

Body Location

Intraobserver CV (%)

Interobserver CV (%)

anterior abdominal wall thickness

2.2

5.2

subscapular thickness

2.5

6.1

lean body areas of the thigh

1.9

3.9

lean body areas of  the arm

2.3

5.6

fat body areas of thigh

2.9

5.9

fat body areas of arm

4.4

7.3

 Independent Variables

  • Maternal age (years)
  • Parity (n)
  • Prepregnancy BMI (kg/m2)
  • Maternal weight gain (kg)
  • 1-h GCT value (mg/dL)
  • Maternal blood glucose values (mg/dL)
  • Preprandial
  • 1-h postprandial
  • 2-h postprandial
  • Compliance (%)
  • Gestational age at delivery (weeks)
  • Neonatal sex (% boys)
  • Birth weight (g)
  • AGA
  • LGA - large for gestational age when birth weight was  > 90th  percentile based on standard growth of population
  • SGA - small for gestational age when birth weight was < 10th percentile based on standard growth of population.
  • Ponderal index (units)- ratio between 100 times the weight in grams and the cube of length in centimeters.

Control Variables

 

 

Description of Actual Data Sample:

Initial N: 228 subjects were recruited for the study. From the recruitment population, 189 women who had uneventful pregnancies, did not receive drugs known to affect glucose metabolism (e.g., steroids and Beta 2-sympathomimetics) through gestation, and delivered term (37-42 weeks completed) live-born infants.  

Attrition (final N):  as above

Age: See Table 1

Ethnicity: Caucasian

Other relevant demographics:

Anthropometrics

Location:The Department of Gynecology, Perinatology and Human Reproduction, University of Florence, Florence, Italy.

Summary of Results:

No differences were found in regard to the maternal characteristics between the study sub-group and the 39 excluded women.

Table 1 –Maternal and neonatal characteristics 

 

Group 1

Group 2

P

n

66

123

-

Maternal age (years)

32.5(26-39)

33.5(26-39)

NS

Parity (n)

1(0-2)

1 (0-2)

NS

Prepregnancy BMI (kg/m2 )

22.1 (19.8-25.3)

22.7 (19-25)

NS

Maternal weight gain (kg)

11.1 (8-14)

11.5 (9-5)

NS

1-h GCT value (mg/dl)

156.3+ 19.1

112.3 + 19.4

<0.0001

Maternal blood glucose values(mg/dl)

-

-

-

Preprandial

76.9+ 11.12

61.3 +13.4

<0.003

1-h postprandial

120.9 +  12.8

97.5 + 11.2

<0.001

2-h postprandial

100.5 + 10.8

86.2 +11.7

<0.002

Compliance (%)*

94.3 + 2.3

93.6 + 2.6

NS

Gestational age at delivery (weeks)

39.2 + 1.6

39.8 + 1.4

NS

Neonatal sex (% boys)

34(51.5)

61(49.6) 

NS

Birth weight (g)

3,561.8 + 351.3

3,382.2+ 348.2

<0.04

AGA

47(71.2)

104(84.6)

<0.04

LGA

16(24.3)

10(8.1)

<0.004

SGA

3(4.5)

9(7.3)

NS

Ponderal index (units)

2.71 + 0.21

2.53 + 0.12

<0.01

Data are median (range), means + SD, or n (%). *Patient compliance with self-monitoring of blood glucose was defined as the percentage of the 30 glucose measurements prescribed by the protocol during the 4 weeks before delivery that were actually performed . AGA, appropriate for gestational age; LGA, large for gestational age; SGA, small for gestational age.

The proportions of variance for which each of the independent variables (fetal body composition) were responsible is shown in Table 2.

Table 2 – Stepwise, regression analysis: factors correlating with fetal body composition

Dependent and independent variables

 R2

 Delta R2

-

-

-

Lean body mass

-

-

Head Circumference

-

-

Gestational age

0.70

-

(Gestational age) 2

0.87

0.17

Neonatal sex

0.92

0.05

Femur length

-

-

Gestational age

0.90

-

(Gestational age) 2

0.95

0.05

Mid-upper arm central area

-

-

Gestational age

0.65

-

(Gestational age) 2

0.70

0.05

Neonatal sex

0.77

0.07

Mid-thigh central area

-

-

Gestational age

0.60

-

(Gestational age) 2

0.73

0.13

Neonatal sex

0.78

0.05

2-h postprandial

0.82

0.04

Fat body mass

-

-

Anterior abdominal thickness

-

-

Group

0.48

-

(Gestational age) 2

0.52

0.04

1-h postprandial

0.67

0.15

Subscapular thickness

-

-

Group

0.40

-

(Gestational age) 2

0.44

0.04

1-h postprandial

0.55

0.11

Prepregnancy BMI

0.58

0.03

Mid-upper arm area

-

-

Group

0.45

-

(Gestational age) 2

0.48

0.03

1-h postprandial

0.60

0.12

2-h postprandial

0.62

0.02

Mid-thigh area

-

-

Group

0.45

-

(Gestational age) 2

0.49

0.04

1-h postprandial

0.61

0.05

2-h postprandial

0.64

0.03

Other Findings

  • With respect to all parameters used to evaluate fetal lean body mass, no differences were observed between groups 1 and 2.
  • The factors that were significantly associated head circumference were gestational age and sex (male)
  • Gestational age was the only independently associated factor for femur length.
  • For the central lean area of the mid-upper arm, independently associated factors were gestational age and sex.
  • For the central lean areas of the mid-thigh, independently associated factors were gestational age, sex (male), and maternal 2-h postprandial glucose values.
  • With respect to fetal fat body mass, the growth of the anterior abdominal wall thickness was significantly greater in group 1 than in group 2 from the 26th week to the end of pregnancy. The factors that were significantly associated with this measurement were gestational age and maternal 1-h postprandial glucose values.
  • The growth of the subscapular thickness was significantly greater in group 1 from the 26th week to the end of pregnancy. The factors that were significantly and independently associated with this measurement were gestational age, maternal 1-h postprandial glucose values, and prepregnancy BMI.
  • The growth of the mid-upper arm subcutaneous was significantly greater in group 1 from the 25th week to the end of pregnancy. The factors that were significantly and independently associated with this measurement were gestational age and 1- and 2- h postprandial values.
  • The growth of the mid-thigh subcutaneous area was significantly greater in group 1 from the 25th week to the end of the pregnancy. The factors that were significantly and independently associayed with this measurement were gestational age, 1-h postprandial glucose values, and prepregnancy BMI.

 

Author Conclusion:
  • Study suggested the possibility of using sonographically determined fetal fat and lean body mass measurements as indicated by body composition.
  • The assessment of the noted parameters, achievable in a noninvasive and reproducible fashion in pregnancies complicated by glucose intolerance, might enable the real-time detection of fetal overgrowth and disproportion, thus opening the possibility of exploring interventions that would limit fetal fat accretion, birth weight, and potential resulting morbidity.

Limitations:

  • The results need confirmation and verification in glucose intolerant pregnant women to legitimize possible clinical use.
  • The lack fat mass measurement in the neonate does not allow comparison between sonographic findings and those obtained postnatally.
  • Standard curves lean and fat mass should be defined in a large normal population.
Funding Source:
Reviewer Comments:

Analytical longitudinal surveys refer to what epidemiologists term prospective or cohort studies. A Cohort Study is a study in which patients who presently have a certain condition and/or receive a particular treatment are followed over time and compared with another group who are not affected by the condition under investigation. Studies of this kind provide a better opportunity than one time cross sectional studies to examine whether certain behaviors do in fact lead to (or cause) the disease.

The limitations and critique of the study, as stated by the authors appear to be very appropriate.

 

 

Quality Criteria Checklist: Primary Research
Relevance Questions
  1. Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) Yes
  2. Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? Yes
  3. Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? Yes
  4. Is the intervention or procedure feasible? (NA for some epidemiological studies) Yes
 
Validity Questions
1. Was the research question clearly stated? Yes
  1.1. Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? Yes
  1.2. Was (were) the outcome(s) [dependent variable(s)] clearly indicated? Yes
  1.3. Were the target population and setting specified? Yes
2. Was the selection of study subjects/patients free from bias? Yes
  2.1. Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? Yes
  2.2. Were criteria applied equally to all study groups? Yes
  2.3. Were health, demographics, and other characteristics of subjects described? Yes
  2.4. Were the subjects/patients a representative sample of the relevant population? Yes
3. Were study groups comparable? Yes
  3.1. Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) N/A
  3.2. Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? Yes
  3.3. Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) Yes
  3.4. If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? Yes
  3.5. If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) N/A
  3.6. If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? N/A
4. Was method of handling withdrawals described? N/A
  4.1. Were follow-up methods described and the same for all groups? N/A
  4.2. Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) N/A
  4.3. Were all enrolled subjects/patients (in the original sample) accounted for? N/A
  4.4. Were reasons for withdrawals similar across groups? N/A
  4.5. If diagnostic test, was decision to perform reference test not dependent on results of test under study? N/A
5. Was blinding used to prevent introduction of bias? Yes
  5.1. In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? N/A
  5.2. Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) N/A
  5.3. In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? Yes
  5.4. In case control study, was case definition explicit and case ascertainment not influenced by exposure status? N/A
  5.5. In diagnostic study, were test results blinded to patient history and other test results? N/A
6. Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? N/A
  6.1. In RCT or other intervention trial, were protocols described for all regimens studied? N/A
  6.2. In observational study, were interventions, study settings, and clinicians/provider described? N/A
  6.3. Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? N/A
  6.4. Was the amount of exposure and, if relevant, subject/patient compliance measured? N/A
  6.5. Were co-interventions (e.g., ancillary treatments, other therapies) described? N/A
  6.6. Were extra or unplanned treatments described? N/A
  6.7. Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? N/A
  6.8. In diagnostic study, were details of test administration and replication sufficient? N/A
7. Were outcomes clearly defined and the measurements valid and reliable? Yes
  7.1. Were primary and secondary endpoints described and relevant to the question? Yes
  7.2. Were nutrition measures appropriate to question and outcomes of concern? Yes
  7.3. Was the period of follow-up long enough for important outcome(s) to occur? Yes
  7.4. Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? Yes
  7.5. Was the measurement of effect at an appropriate level of precision? Yes
  7.6. Were other factors accounted for (measured) that could affect outcomes? Yes
  7.7. Were the measurements conducted consistently across groups? Yes
8. Was the statistical analysis appropriate for the study design and type of outcome indicators? Yes
  8.1. Were statistical analyses adequately described and the results reported appropriately? Yes
  8.2. Were correct statistical tests used and assumptions of test not violated? Yes
  8.3. Were statistics reported with levels of significance and/or confidence intervals? Yes
  8.4. Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? N/A
  8.5. Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? Yes
  8.6. Was clinical significance as well as statistical significance reported? Yes
  8.7. If negative findings, was a power calculation reported to address type 2 error? N/A
9. Are conclusions supported by results with biases and limitations taken into consideration? Yes
  9.1. Is there a discussion of findings? Yes
  9.2. Are biases and study limitations identified and discussed? Yes
10. Is bias due to study's funding or sponsorship unlikely? Yes
  10.1. Were sources of funding and investigators' affiliations described? Yes
  10.2. Was the study free from apparent conflict of interest? Yes